Foamix Pharmaceuticals to Participate in a Panel Discussion at the Dermatology Innovation Forum

February 23, 2017 at 8:01 AM EST

REHOVOT, Israel, and BRIDGEWATER, New Jersey, Feb. 23, 2017 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that Dr. Dov Tamarkin, CEO, will participate in a panel discussion entitled "Exciting New Therapeutics: Emerging Public Company Showcase," at the 3rd Annual Dermatology Innovation Forum, being held at the Hyatt Regency Orlando in Orlando, Florida on March 2, 2017.


Panel Presentation:  "Exciting New Therapeutics: Emerging Public Company Showcase"

Date:               Thursday, March 2, 2017

Time:               10:50am Eastern Time

Location:         R Room, Hyatt Regency, Orlando

About the Dermatology Innovation Forum

The mission of the Dermatology Innovation Forum is to build a community of dermatologists and their colleagues who are excited about developing ideas into products which can substantially improve skin health.  Held in association with the American Academy of Dermatology annual meeting, the forum focuses on educating participants about inspiring innovations that can provide a basis for the generation of important dermatology products and services. By including physicians, researchers, inventors, investors, strategic corporate partners, service providers, government regulators, patient advocates, and other stakeholders, this forum also provides a unique networking venue for its attendees to communicate with, learn from, and collaborate with each other.

About Foamix Pharmaceuticals Ltd.

Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy.

Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, FMX103 for the treatment of moderate-to-severe rosacea, FMX102 for the treatment of impetigo, and FDX104, our doxycycline foam for the management of acne-like rash induced by EGFRI anticancer drugs.

In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including Bayer HealthCare and others.

For more information, please visit


US Investor Relations

Dorit Hayon    

Michael Rice

Foamix Pharmaceuticals Ltd.  

LifeSci Advisors, LLC




To view the original version on PR Newswire, visit:

SOURCE Foamix Pharmaceuticals Ltd.